Pharmasyntez has become the winner of the auction for the right to conclude an offset contract for the supply of seven INNs of antitumor drugs in Moscow. The company undertakes to invest 400 million rubles in the localization of production, and the city provides it with a guaranteed purchase of products over the period of four years, in the amount of 2.4 billion rubles, said Vladimir Efimov, Moscow’s Vice-Mayor.
The first shipments from the facility are expected in 2026. According to Oleg Astafurov, Pharmasyntez’s Vice-president for government relations, this contract will expand the geographical presence of the company and increase its competitiveness, which is, along with other reasons, due to the fact that now “we can engage the best research centers of Russia’s capital for the development of new innovative medicines.” Now Pharmasyntez has its pharmaceutical enterprises in five Russian cities: Saint Petersburg, Tyumen, Irkutsk, Bratsk, and Ussuriysk.
“Contracts on pharmaceuticals production and supply make it possible to establish uninterrupted provision of Muscovites with medicines. <…> The city has concluded six offset contracts with investors for the supply of more than 80 INNs. The total volume of investments in the creation of production facilities will amount to 12.5 billion rubles,” the press service of the Department of Investment and Industrial Policy of Moscow noted.
This is the ninth offset contract concluded in Moscow since 2016, when the mechanism was introduced. In addition to Pharmasyntez, Moscow has signed contracts for the supply of medicines with Moscow Endocrine Plant, Biocad, Velpharm-M, R-Opra, and R-Pharm.
In March, for example, it became known that a new seven-year contract was concluded with R-Pharm for the supply of four INNs, including immunosuppressants and antitumor drugs.
